ERBA Diagnostics Enters Brazilian Sector with Leading-Edge Clinical Testing Portfolio
|
By LabMedica International staff writers Posted on 02 Nov 2014 |
|
ERBA Diagnostics, Inc. (Miami Lakes, FL, USA) has announced that an integrated portfolio of its latest in vitro diagnostics platforms and reagents are now being made available to hospitals, references labs, and physician clinics in Brazil. The product line includes a comprehensive suite of instruments, reagents, and kits for immunology, clinical chemistry, hematology, diabetes, and infectious disease testing, with an emphasis on hematology and clinical chemistry. ERBA Diagnostics intends to introduce this suite of products as the product registrations in Brazil are completed.
"We believe that our line of products is ideally suited to address the rapidly growing medical needs for Brazil," said Mohan Gopalkrishnan, chief executive officer of ERBA Diagnostics, "Within Brazil, there is a predominance of smaller, local healthcare providers. We expect that our proprietary instruments and reagents will allow these providers access to the latest diagnostics at a scale and price point that serves their needs. Our initial experience in Brazil during the past three months has been encouraging and we look forward to expanding the number of clinics and hospitals we serve, as we continue to register the full suite of our products in Brazil."
The estimated market for in vitro diagnostics products in Brazil was approximately USD 1.0 billion in 2012 and is expected to grow to USD 1.4 billion by 2017, far exceeding the rate of growth in the world market for in vitro diagnostics products. Brazil has a population of 200 million people and the country is undergoing a rapid expansion of the elderly and middle class. These factors are contributing to the increased demand for clinical testing at both public and private healthcare providers as a means to inform treatment, improve outcomes, and reduce overall healthcare expenditures.
"Given our commitment to Brazil, and as part of our continued effort to streamline our operations, we are evaluating opportunities to establish local manufacturing capabilities," added Mr. Gopalkrishnan, "We believe that establishing manufacturing capabilities in Brazil will ultimately allow us to operate as efficiently as possible while simultaneously positioning us to best serve the diagnostic testing needs of the country's healthcare providers."
Related Links:
ERBA Diagnostics
"We believe that our line of products is ideally suited to address the rapidly growing medical needs for Brazil," said Mohan Gopalkrishnan, chief executive officer of ERBA Diagnostics, "Within Brazil, there is a predominance of smaller, local healthcare providers. We expect that our proprietary instruments and reagents will allow these providers access to the latest diagnostics at a scale and price point that serves their needs. Our initial experience in Brazil during the past three months has been encouraging and we look forward to expanding the number of clinics and hospitals we serve, as we continue to register the full suite of our products in Brazil."
The estimated market for in vitro diagnostics products in Brazil was approximately USD 1.0 billion in 2012 and is expected to grow to USD 1.4 billion by 2017, far exceeding the rate of growth in the world market for in vitro diagnostics products. Brazil has a population of 200 million people and the country is undergoing a rapid expansion of the elderly and middle class. These factors are contributing to the increased demand for clinical testing at both public and private healthcare providers as a means to inform treatment, improve outcomes, and reduce overall healthcare expenditures.
"Given our commitment to Brazil, and as part of our continued effort to streamline our operations, we are evaluating opportunities to establish local manufacturing capabilities," added Mr. Gopalkrishnan, "We believe that establishing manufacturing capabilities in Brazil will ultimately allow us to operate as efficiently as possible while simultaneously positioning us to best serve the diagnostic testing needs of the country's healthcare providers."
Related Links:
ERBA Diagnostics
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Repetitive Pipette
VWR® Stepper Pro
Prefilled Tubes
Prefilled 5.0ml Tubes
Latest Industry News
- Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
- Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
- Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
- Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
- Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
- Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
- Seed Amplification Test Expands Access to Neurodegenerative Disease Testing
- Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
- Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
- Merck KGaA to Acquire Bio-Techne, Expanding Life Science Portfolio
- Agilent Strengthens Pathology Capabilities Through Biocare Acquisition
- Partnership Integrates Automated DNA Extraction with Single-Molecule Digital PCR
- Project Aims to Develop First Single-Cell Assay for ADC Therapies
- Agreement Supports pTau217-Based Alzheimer’s Blood Test Development
- Collaboration Aims to Broaden Access to NETosis-Linked Disease Testing
- Partnership Aims to Improve Transplant Monitoring Across Care Continuum
Channels
Clinical Chemistry
view channel
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more
Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
Cancer cells require large amounts of nutrients to grow and proliferate, and amino acids support key processes including protein formation, energy production, and DNA synthesis. Colorectal cancer is marked... Read more
Molecular Diagnostics
view channel
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read more
Hematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more
Immunology
view channel
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more
Microbiology
view channel
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read more
New Rapid Ebola Antigen Test Detects Infection at Point of Care
A serious Ebola epidemic centered in the Democratic Republic of the Congo has caused hundreds of deaths and triggered a global public health emergency, with cases also reported in Uganda.... Read more
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read more
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
